参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249.[2]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2019[J].CA Cancer J Clin,2019,69(1):7-34.[3]Bray F,Carstensen B,M?覬ller H,et al.Incidence trends of adenocarcinoma of the cervix in 13 European countries[J].Cancer Epidemiol Biomarkers Prev,2005,14(9):2191-2199.[4]Bray F,Loos AH,McCarron P,et al.Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening[J].Cancer Epidemiol Biomarkers Prev,2005,14(3):677-686.[5]Utada M,Chernyavskiy P,Lee WJ,et al.Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012[J].Int J Cancer,2019,144(9):2144-2152.[6]Castanon A,Sasieni P.Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern?[J].Prev Med,2018,107:21-28.[7]McDonald SA,Qendri V,Berkhof J,et al.Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing[J].Cancer Causes Control,2017,28(3):203-214.[8]Jedy-Agba E,Joko WY,Liu B,et al.Trends in cervical cancer incidence in sub-Saharan Africa[J].Br J Cancer,2020,123(1):148-154.[9]Pilleron S,Cabasag CJ,Ferlay J,et al.Cervical cancer burden in Latin America and the Caribbean:Where are we?[J].Int J Cancer,2020,147(6):1638-1648.[10]Bray F,Lortet-Tieulent J,Znaor A,et al.Patterns and Trends in Human Papillomavirus-Related Diseases in Central and Eastern Europe and Central Asia[J].Vaccine,2013,31:H32-H45.[11]Ran Z,Wu S,Ma Z,et al.Advances in exosome biomarkers for cervical cancer[J].Cancer Med,2022,11(24):4966-4978.[12]Rajaram S,Gupta B.Screening for cervical cancer: Choices & dilemmas[J].Indian J Med Res,2021,154(2):210-220.[13]Burmeister CA,Khan SF,Sch?覿fer G,et al.Cervical cancer therapies: Current challenges and future perspectives[J].Tumour Virus Res,2022,13:200238. [14]Monk BJ,Enomoto T,Kast WM,et al.Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials[J].Cancer Treat Rev,2022,106:102385. [15]Bedell SL,Goldstein LS,Goldstein AR,et al.Cervical Cancer Screening: Past, Present, and Future[J].Sex Med Rev,2020,8(1):28-37. [16]Marquina G,Manzano A,Casado A.Targeted Agents in Cervical Cancer: Beyond Bevacizumab[J].Curr Oncol Rep,2018,20(5):40.[17]Chen S,Yang D,Lei C,et al.Identification of crucial genes in abdominal aortic aneurysm by WGCNA[J].PeerJ,2019,7:e7873.[18]Gallon J,Rodriguez-Calero A,Benjak A,et al.DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations[J].Cancer Res,2023,83(8):1203-1213. [19]Yang Y,Yang W,Su X,et al.Prognostic value and immunological role of PTPN21 in pan-cancer analysis[J].Cent Eur J Immunol,2023,48(2):111-125.[20]Momin ID,Rigler J,Chitrala KN.Analysis of Potential Biomarkers in Frontal Temporal Dementia: A Bioinformatics Approach[J].Int J Mol Sci,2023,24(19):14910.[21]Bhartiya D,Singh J.FSH-FSHR3-stem cells in ovary surface epithelium: basis for adult ovarian biology, failure, aging, and cancer[J].Reproduction,2015,149(1):R35-R48.[22]Kilanowska A,Zió?覥kowska A,Stasiak P,et al.cAMP-Dependent Signaling and Ovarian Cancer[J].Cells,2022,11(23):3835.[23]Yue W,Ma J,Xiao Y,et al.The Apoptotic Resistance of BRCA1-Deficient Ovarian Cancer Cells is Mediated by cAMP[J].Front Cell Dev Biol,2022,10:889656.[24]Stevens LE,Peluffo G,Qiu X,et al.JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States[J].Cancer Res,2023,83(2):264-284.[25]Feng Z,Li L,Tu Y,et al.Identification of Circular RNA-Based Immunomodulatory Networks in Colorectal Cancer[J].Front Oncol,2021,11:779706.[26]Sasca D,Szybinski J,Schüler A,et al.NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML[J].Blood,2019,133(21):2305-2319.[27]Gress V,Roussy M,Boulianne L,et al.CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216[J].Blood Adv,2024,8(1):112-129.[28]Zhao L,Wu X,Zhang Z,et al.ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells[J].Cancer Sci,2023,114(6):2650-2663.[29]Yang B,Huang S,Chen H,et al.DNMT3B regulates proliferation of A549 cells through the microRNA-152-3p/NCAM1 pathway[J].Oncol Lett,2022,23(1):11.[30]Wang Z,Wang T,Wu G,et al.Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer[J].J Clin Med,2023,12(5):1892.[31]Sarafidis M,Lambrou GI,Zoumpourlis V,et al.An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer[J].Cancers (Basel),2022,14(14):3358.[32]Liu Y,Kramer JR,Sandulache VC,et al.Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort[J].Cancer Res,2023,83(3):386-397.[33]Timpanaro A,Piccand C,Uldry AC,et al.Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma[J].Int J Mol Sci,2023,24(3):2601.[34]Odarenko KV,Salomatina OV,Chernikov IV,et al.Soloxolone Methyl Reduces the Stimulatory Effect of Leptin on the Aggressive Phenotype of Murine Neuro2a Neuroblastoma Cells via the MAPK/ERK1/2 Pathway[J].Pharmaceuticals (Basel),2023,16(10):1369.[35]Gabriele C,Aracri F,Prestagiacomo LE,et al.Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables[J].Clin Proteomics,2023,20(1):52.[36]Nakamura N,Rogers P,Eggerson R,et al.Translational Research for Identifying Potential Early-stage Prostate Cancer Biomarkers[J].Cancer Genomics Proteomics,2023,20(1):1-8.[37]Balraj AS,Muthamilselvan S,Raja R,et al.PRADclass: Hybrid Gleason Grade-Informed Computational Strategy Identifies Consensus Biomarker Features Predictive of Aggressive Prostate Adenocarcinoma[J].Technol Cancer Res Treat,2024,23:15330338231222389.[38]Cao R,Li J,Zhang L,et al.Analysis of Genes Associated with Both Neural Tube Defects and Neuroectodermal Tumors[J].Med Sci Monit,2022,28:e936079.[39]Seymour F,Cavenagh JD,Mathews J,et al.NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma[J].Blood Adv,2022,6(17):5152-5159.[40]Pánisová E,Lünemann A,Bürgler S,et al.Reduced frequency of cytotoxic CD56 CD16 NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma[J].Cancer ImmunolImmunother,2022,71(1):13-24.[41]Guzman De Avila J,Silvera-Redondo C,Alviz-Amador A.Bioinformatic Analysis of Plus Gene Expression Related to Progression from Leukoplakia to Oral Squamous Cell Carcinoma[J].Asian Pac J Cancer Prev,2022,23(11):3833-3842.[42]Wang ZZ,Li XH, Wen XL,et al.Integration of multi-omics data reveals a novel hybrid breast cancer subtype and its biomarkers[J].Front Oncol,2023,13:1130092.[43]Bitaraf M,Mahmanzar M,Zafari N,et al.The potential key genes and pathways associated with Wilms tumor in quest of proper candidates for diagnostic and therapeutic purposes[J].Sci Rep,2022,12(1):17906.[44]V?覿yrynen JP,Haruki K,Lau MC,et al.Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment[J].Cancer Immunol Res,2022,10(2):215-227.
相似文献/References:
[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Journal of Medical Information,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Journal of Medical Information,2018,31(11):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Journal of Medical Information,2018,31(11):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[4]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Journal of Medical Information,2018,31(11):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[5]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Journal of Medical Information,2018,31(11):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[6]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Journal of Medical Information,2018,31(11):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[7]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者
分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(11):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[8]吴晓玲,周桂华.miR-187在宫颈癌中的表达与临床病理关系的研究[J].医学信息,2018,31(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Journal of Medical Information,2018,31(11):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[9]夏为书,彭莉贞,钟清玲.我国宫颈癌患者配偶生活质量评价的研究现状[J].医学信息,2018,31(23):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
XIA Wei-shu,PENG Li-zhen,ZHONG Qing-ling.Research Status of Spouse Quality of Life Evaluation of Cervical Cancer Patients in China[J].Journal of Medical Information,2018,31(11):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
[10]邢 均.全身麻醉联合硬膜外麻醉在宫颈癌手术中的应用及效果评价[J].医学信息,2019,32(01):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
XING Jun.Application and Evaluation of General Anesthesia Combined with Epidural Anesthesia in[J].Journal of Medical Information,2019,32(11):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
[11]李得意,张路瑶,许 杨,等.基于生物信息学方法探究SERINC2基因在宫颈癌中的表达及其作用机制[J].医学信息,2023,36(14):1.[doi:10.3969/j.issn.1006-1959.2023.14.001]
LI De-yi,ZHANG Lu-yao,XU Yang,et al.The Expression and Mechanism of SERINC2 Gene in Cervical Cancer Based on Bioinformatics Methods[J].Journal of Medical Information,2023,36(11):1.[doi:10.3969/j.issn.1006-1959.2023.14.001]